Condition: Breast Cancer · Sponsor: Institut Bergonié
Trial assessing the prognostic value of ctDNA mutations from samples taken sequentially in patients with invasive breast cancer initially treated with neoadjuvant chemotherapy and whose tumor is not in complete histological response.
This description comes directly from the study's public registry record.
Hervé BONNEFOI, MD, PhD · +33 5 56 33 32 69 · h.bonnefoi@bordeaux.unicancer.fr
Simone MATHOULIN-PELISSIER, MD, PhD · s.mathoulin@bordeaux.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut Bergonie | Bordeaux, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03357120